BNT162b2 vaccine has become one of the most prevalent vaccines against the COVID-19 and is currently the main vaccine used in Israel. Since marketing and the beginning of use of the vaccine, we and others have reported. of the development of post vaccination myocarditis. In this study the investigators wish to explore the long term impact on 150 patients who have been diagnosed with myocarditis or multisystem inflammatory syndrome (MIS) in the year following their diagnosis of Myocarditis.
Aim of Study The primary aim of the study is to evaluate the impact of long term impact of myocarditis which has been developed secondary to Covid 19 vaccine or Covid 19 infection. The primary end points of the study will be functional evaluations of the patients using clinical evaluation that includes questionnaires, ECG findings, evaluation of the systolic and diastolic function of the heart using echocardiogram or cardiac MRI, laboratory tests including troponin, CPK, CRP, Pro-BNP, and cytokines/chemokines. Methods In this prospective study patients will be recruited from health care providers The selected patients will come to Hadassah hospital within 6 and 12 months after they have been diagnosed with myocarditis. Upon the patients arrival they will sign the informed consent, the investigators will draw blood tests and the participants will perform an echocardiogram according to the special protocol and will perform cardiac- MRI according to the myocarditis protocol. Patients will fulfill health questionnaires. that may include 36 Health Survey Questionnaire (SF-36); Scores on the European Quality of Life-5 Dimensions (EQ-5D) survey, which is also health-related quality of life score; the Scores on the European Quality of Life Visual Analogue Scale (EQ-VAS); Kansas City Cardiomyopathy Questionnaire (KCCQ). the Investigators will obtain blood samples from all the patients: complete blood count, c- reactive protein, troponin, CPK, Pro-BNP, liver and kidney functions, magnesium and cytokines. In addition, all participants will undergo echocardiogram test to evaluate their systolic and diastolic function of the heart. Ethical Considerations The study poses no danger to the participants. It has the potential to improve the understanding of the impact myocarditis post COVID-19 MRNA vaccine on the quality of life of those patients and provide a descent follow-up for the participant. Any participant will sign on informed consent form.
Study Type
OBSERVATIONAL
Enrollment
150
This is an observational study, with no intervention.
Hadassah Medical Center
Jerusalem, Israel
RECRUITINGTo assess troponin levels in patients that developed acute myocarditis
troponin levels in each clinical visit will be documented
Time frame: 3 years
To assess PRO-BNP levels in patients that developed acute myocarditis
PRO-BNP levels in each clinical visit will be documented
Time frame: 3 years
To assess CRP levels in patients that developed acute myocarditis
CRP levels in each clinical visit will be documented
Time frame: 3 years
To assess cardiac MRI in patients that developed acute myocarditis
Cardiac MRI will be performed at least yearly and evaluated for regionally increased signal in T2-weighted images; Late gadolinium enhancement in a nonischemic pattern, Increased native T1 values on a 3T magnet.
Time frame: 3 years
To assess echocardiogram in patients that developed acute myocarditis
echocardiogram will be performed at least yearly and defined as normal, ST-segment elevation, with Diffuse or Non-diffuse changes, T-wave changes, Atrial fibrillation or non-sustained ventricular tachycardia.
Time frame: 3 years
To assess health quality by a questionnaire in patients that developed acute myocarditis
EQ-5D will be fill at least once a year. Descriptive analysis of EQ-5D profile at each observation and analysis of changes between repeated observations. Cluster analysis can be used.
Time frame: 3 years
To assess heart failure questionnaire in patients that developed acute myocarditis
KCCQ will be fill at least once a year.
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cytokine in Patients after myocarditis
To assess cytokines by measuring the serum concentrations
Time frame: 3 years
Chemokine in Patients after myocarditis
To assess chemokines by measuring the serum concentrations
Time frame: 3 years
Hematopoietic Growth Factors (HGF)in patients after myocarditis
To assess Hematopoietic Growth Factors in patients with COVID-19 by measuring the To assess HGF by measuring the serum concentrations
Time frame: 3 years
Complement in patients after myocarditis
assess complement factors by measuring the serum concentrations
Time frame: 3 years